Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to gnrh stimulation regardless of their androgen status: Comparison of the Rotterdam and Androgen excess society diagnostic criteria

Neuroendocrinology Letters

Volumn 32, Issue 6, 2011, Pages 847-856

  Lewandowski, Krzysztof C ^a,b   Cajdler łuba, Agata ^b   Bienḱiewicz, Magłorzata ^a   Lewinśki, Andrzej ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Androgen status; GnRH; Menstrual irregularities; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; FOLLITROPIN; GONADORELIN; GONADOTROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; AMENORRHEA AND OLIGOMENORRHEA; ARTICLE; CONTROLLED STUDY; FEMALE; GONADOTROPIN BLOOD LEVEL; GONADOTROPIN RELEASE; HUMAN; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 84857430589     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF (2006). Androgen Excess Society. Positions Statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91: 4237-4245. (Pubitemid 44833391)
2. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO (2004). The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89: 2745-2749. (Pubitemid 38766360)
3. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS (1995). Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 10: 2705-2712.
4. Balen AH, Laven JS, Tan SL (2003). Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 9: 505-514. (Pubitemid 38072143)
5. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA (1989). Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. New Engl J Med 320: 559-565. (Pubitemid 19070540)
6. Barth JH, Yasmin E, Balen AH (2007). The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxford) 67: 811-815. (Pubitemid 350135121)
7. Blank SK, McCartney CR, Marshall JC (2006). The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 12: 351-361. (Pubitemid 43923410)
8. Boots LR, Potter S, Potter D, Azziz R (1998). Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertility Steril 69: 286-292. (Pubitemid 28117108)
9. Chhabra S, McCartney CR, Yoo RY, Eagleson CA, Chang RJ, Marshall JC (2005). Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab 90: 2810-2815. (Pubitemid 40686328)
10. Conway GS, Honour JW, Jacobs HS (1989). Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin Endocrinol (Oxford) 30: 459-470. (Pubitemid 19110020)
11. Ehrmann DA (2005). Polycystic ovary syndrome. New Engl J Med 352: 1223-1236.
12. Ehrmann DA, Barnes RB, Rosenfield RL (1995) Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine Rev 16: 322-353.
13. Fears TR, Ziegler RG, Donaldson JL, Falk RT, Hoover RN, Stanczyk FZ, Vaught JB, Gail MH (2000). Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epidemiol Biomarkers Preview 9: 403-412. (Pubitemid 30265784)
14. Ferriman D, Gallwey JD (1961). Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21: 1440-1447.
15. Ferris HA, Shupnik MA (2006). Mechanisms for pulsatile regulation of the gonadotropin subunit genes by GnRH1. Biol Reprod 74: 993-998. (Pubitemid 47394279)
16. Jasonni VM, Bulletti C, Naldi S, Di Cosmo E, Cappuccini F, Flamigni C (1991). Treatment of hirsutism by an association of oral cyproproterone acetate and transdermal 17-β-estradiol. Fertil Steril 55: 742-745.
17. Karasek M, Pawlikowski M, Lewinski A (2006). Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynol Pol Polish J Endocrinol 57: 656-662.
18. Kazer RR, Kessel B, Yen SS (1987). LH pulse frequency in women with PCO. J Clin Endocrinol Metab 65: 233-236.
19. Koskinen P, Penttilä TA, Anttila L, Erkkola R, Irjala K (1996). Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome. Fertil Steril 65: 517-522. (Pubitemid 26069105)
20. Lawson MA, Jain S, Sun S, Patel K, Malcolm PJ, Chang RJ (2008). Evidence for insulin suppression of baseline luteininising hormone in women with polycystic ovarian syndrome and normal women. J Clin Endocrinol Metab 93: 2089-2096. (Pubitemid 351831520)
21. March WA, Moore VM, Willson KJ, Phillips Dl, Norman RJ, Davies MJ (2010). The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25: 544-551.
22. Marshall JC, Dalkin AC, Haisenleder DJ, Paul SJ, Ortolano GA, Kelch RP (1991). Gonadotropin releasing hormone pulses: regulators of gonadotropin synthesis and ovolulatory cycles. Rec Prog Horm Res 1991 47: 155-187.
23. Marshall JC, Eagleson CA (1999). Neuroendocrine aspects of polycystic ovary syndrome. Endocrinol Metab Clin North Am 28: 295-324. (Pubitemid 29242715)
24. Matsuda M, DeFronzo R (1999). Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabet Care 9: 1462-1470.
25. Matthews DR, Hosker JP, Rudenski AS (1985). Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
26. Milewicz A, Silber D, Mielecki T (1983) The origin of androgen synthesis in polycystic ovary-syndrome. Obstetr Gynecol 62: 601-614.
27. Neal-Perry G, Lebesgue D, Lederman M, Shu J, Zeevalk GD, Etgen AM (2009). The excitatory peptide kisspeptin restores the luteinizing hormone surge and modulates amino acid neurotransmission in the medial preoptic area of middle-aged rats. Endocrinology 150: 3699-3708.
28. Nippoldt TB, Reame NE, Kelch RP, Marshall JC (1989). The roles of estradiol and progesterone in decreasing luteinizing hormone pulse frequency in the luteal phase of the menstrual cycle. J Clin Endocrinol Metab 69: 67-76. (Pubitemid 19172428)
29. Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A (2007). 17-Hydroxyprogesterone responses to gonadotropin-releasing hormone disclose phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 92: 4208-4217. (Pubitemid 350074733)
30. Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC (1998). Polycystic ovary syndrome: Evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 83: 582-590. (Pubitemid 28496543)
31. Patel K, Coffler MS, Dahan MH, Malcom PJ, Deutsch R, Chang RJ (2004). Relationship of GnRH-stimulated LH release to episodic LH secretion and baseline endocrine-metabolic measures in women with polycystic ovary syndrome. Clin Endocrinol (Oxford) 60: 67-74. (Pubitemid 38183500)
32. Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z (1993). Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann New York Acad Sci 687: 162-181. (Pubitemid 23217935)
33. Stewart PM, Penn R, Holder R, Parton A, Ratcliffe JG, London DR (1993). The hypothalamo-pituitary-adrenal axis across the normal menstrual cycle and in polycystic ovary syndrome. Clin Endocrinol (Oxford) 38: 387-391. (Pubitemid 23105071)
34. Taylor AE (1998). Polycystic ovary syndrome. Endocrinol Metabc Clin N Am 27: 877-902.
35. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, Hall JE (1997). Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 82: 2248-2256. (Pubitemid 27287593)
36. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47.
37. White D, Leigh A, Wilson C, Donaldson A, Franks S (1995). Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxford) 42: 475-481.